People who need a lung transplant can only wait and hope that a
donor organ will materialize in time. But all too often, time runs out.
In response to the United States' critical shortage of donor
organs, researchers have been racing to develop artificial organs that would
serve as a "bridge" to transplantation. One such device is the BioLung,
which may be tested in people soon.
Recommended Related to Lung Disease/Respiratory Problems
Symptoms of pleurisy may include the following:
Severe, fleeting, sharp pain in your chest, often on one side only, when breathing deeply, coughing, moving, sneezing, or even talking.
Severe chest pain that goes away when you hold your breath.
When pleurisy occurs in certain locations of the lungs, the pain can be felt in other parts of the body such as the neck, shoulder, or abdomen.
Rapid, shallow breathing in response to the pain.
Robert Bartlett, MD, surgeon at the University of Michigan
Medical Center, leads the research on the BioLung, and Michigan Critical Care
Consultants (MC3), a company in Ann Arbor, Mich., makes the device. Bartlett is
well known in this field: He is credited with inventing the current generation
of artificial breathing machines.
For eight years, the Ann Arbor team, with support from
scientists at other universities, has been trying to invent a device that can
do what today's machines cannot: supply 100% of a patient's oxygen needs by
using the heart's own pumping power. "It took those eight years of
iterations to meet those design requirements," says Scott Merz, president
The system now used in hospitals is known as ECMO, or
extracorporeal membrane oxygenation. ECMO machines take over the functions of
both the lungs and heart, pumping blood and exchanging carbon dioxide for
oxygen outside the body. Bartlett says ECMO works well for patients who have
had respiratory failure because of infections, such as pneumonia, or trauma,
such as smoke inhalation. They only need to stay on the machine briefly, until
their lungs have healed enough to begin breathing normally.
While ECMO is a short-term lifesaver, it's not good for
long-term use. Many people whose lungs are in such bad shape that they need a
transplant -- such as sufferers of severe emphysema, cystic fibrosis, and
pulmonary fibrosis -- do not survive on ECMO long enough to match them with a
To keep the blood moving through the machine without clotting,
patients get a blood-thinning drug. The blood thinner can cause bleeding. If
blood clots do form, they can damage the brain and other vital organs. What's
more, Merz says the mechanical pumps used in ECMO damage red blood cells -- the
cells that carry oxygen.
The BioLung, however, does not use a mechanical pump, nor does
blood ever leave the body. A little larger than a soda can, it is implanted in
the chest. The patient's own heart pumps blood into the device, which is packed
with hollow plastic fibers perforated with holes so tiny that only gas
molecules can pass through them. As blood filters through the fibers, carbon
dioxide escapes through the holes and is replaced by oxygen from the
surrounding air. Then the blood may go directly back to the heart to be pumped
to the rest of the body, or it may take a spin through the patient's lungs